Previous Frame Next Frame
  • Discover: How Intrexon
    is creating the code for a
    healthier planet

    World Demand
  • Intrexon Energy Partners to
    Generate High-value Oil Products
    from Low-Cost Natural Gas

    DISCOVER

    Intrexon Energy Partners to Generate High-value Oil Products from Low-Cost Natural Gas
  • Optimizing therapeutics production:
    Improving the way we generate active pharmaceutical ingredients

    DISCOVER

    Medistem's Cell Platform Integrated into Intrexon's Technology Suite
  • Intrexon and Johnson & Johnson to
    advance new hair and skin products

    DISCOVER

    Johnson & Johnson Innovation
  • Next-generation fertility solutions

    DISCOVER

    OvaScience
  • World Demand
  • Medistem's Cell Platform Integrated into Intrexon's Technology Suite
  • Medistem's Cell Platform Integrated into Intrexon's Technology Suite
  • Johnson & Johnson Innovation
  • OvaScience

UltraVector® platform to power the next generation of bio-based products
LEAP® automated purification of high value cells
RheoSwitch® precisely controlled expression
IN THE SPOTLIGHT
HEALTH
Collaboration:
Ziopharm and Intrexon are on the path to treating melanoma
FOOD
Extreme Weather:
Drought and the need for novel food applications
ENERGY
Engineering Energy:
Fueling the world with microbes
LATEST NEWS
Intrexon Announces Second Quarter and First Half 2014 Financial Results
GERMANTOWN, Md., Aug. 14, 2014 /PRNewswire/ -- Intrexon Corporation (NYSE: XON), a leader in synthetic biology, today announced its second quarter and first half results for 2014.  Business Highlights and Recent Developments: Acquired Trans Ova Genetics, L.C. ("Trans Ova"), an industry-leading provider of bovine reproductive technologies and the largest producer and supplier of bovine embryos in the United States. The combined technologies of Intrexon and Trans Ova should enable a leadership position in bovine genetics to accelerate efficiency in related food and protein production. Achieved, through Intrexon's Methane Bioconversion platform, the production of farnesene, a key bui...
Intrexon to Announce First Half and Second Quarter 2014 Results and Host Conference Call on August 14th
GERMANTOWN, Md., Aug. 12, 2014 /PRNewswire/ -- Intrexon Corporation (NYSE: XON) today announced it will release first half and second quarter 2014 financial results after the market closes on Thursday, August 14th, 2014.  The Company will host a conference call at 5:30 PM ET to discuss the results and provide a general business update. The conference call may be accessed by dialing 1-877-870-4263 (Domestic US) and 1-412-317-0790 (International) and asking to join the "Intrexon Conference Call."  Participants may also access the live webcast through Intrexon's website in the Investors section under Calendar of Events. About Intrexon Corporation Intrexon Corporation (NYSE: XON) is a...
Intrexon Launches Leadership Platform in Bovine Genetics
Completes Acquisition of Trans Ova GERMANTOWN, Md. and SIOUX CENTER, Iowa, Aug. 11, 2014 /PRNewswire/ -- Intrexon Corporation (NYSE: XON), a leader in synthetic biology, today announced it has completed the acquisition of Trans Ova Genetics, L.C., an industry-leading provider of bovine reproductive technologies.  Trans Ova, as a wholly owned subsidiary of Intrexon, will continue to provide the same level of professional service and dedication to its customers operating under the leadership of David Faber, D.V.M., President, and his management team.  Under the terms of the agreement, Trans Ova stockholders received $60 million in cash, $30 million in Intrexon common stock, and $20 millio...